SCHEMBL24137567

SCHEMBL24137567

c1ccc(NCc2cncc(-c3ccc4[nH]ncc4c3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.56
▸ CLK2 P49760 5/20 0.56
▸ CLK4 Q9HAZ1 5/20 0.56
▸ GSK3B P49841 5/20 0.56
▸ CLK1 P49759 4/20 0.56
▸ DYRK1B Q9Y463 3/20 0.56
▸ CLK3 P49761 2/20 0.56
▸ DYRK3 O43781 2/20 0.56
▸ CDK5 Q00535 2/20 0.56
▸ CDK5R1 Q15078 1/20 0.56
▸ DYRK2 Q92630 1/20 0.56
▸ CCNC P24863 1/20 0.55
▸ CDK8 P49336 1/20 0.55
▸ ROCK2 O75116 8/20 0.53
▸ CDK2 P24941 5/20 0.53
▸ ROCK1 Q13464 5/20 0.53
▸ AURKB Q96GD4 4/20 0.53
▸ RPS6KB1 P23443 3/20 0.53
▸ GSK3A P49840 3/20 0.53
▸ PKN2 Q16513 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137538 0.88 FDPS (0.50) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL24137563 0.88 CCNC (0.61) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL19882573 0.86 DYRK1A (0.57) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL24137790 0.80 CCNC (0.63) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL24137915 0.80 JAK2 (0.57) DYRK1ACLK2CLK4GSK3BCLK3
SCHEMBL25933934 0.79 CCNC (0.44) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL22191140 0.79 PDE3B (0.47) DYRK1ACLK2CLK4GSK3BCLK3
SCHEMBL25933932 0.79 DYRK1A (0.50) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL24137530 0.78 FGFR1 (0.56) DYRK1ACLK2CLK4GSK3BCLK1
SCHEMBL24137909 0.77 CCNC (0.54) DYRK1ACLK2CLK4GSK3BCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 DYRK1A 495/4885CLK2 54/4885CLK4 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback